Strides in STXBP1 Research
What’s new in July of 2026
Researchers from several institutions including CHOP and Texas Children’s Hospital looked at sleep problems across 9 common genetic epilepsies. Across 252 individuals, more than half had sleep issues, yet only one in four received a formal sleep diagnosis. Each genetic epilepsy had unique sleep problems. The most frequent STXBP1-RD sleep features were insomnia symptoms, daytime sleepiness, and especially seizures occurring during sleep or sleep–wake transitions, which affected about one‑third of the group. EEG recordings showed that epileptiform activity during sleep was extremely common in STXBP1, second highest among all genes studied, suggesting that abnormal nighttime brain activity may be a key part of the condition. Overall, the study shows that sleep issues are widespread, under-recognized, and closely tied to seizure control and neuropsychiatric conditions like autism and ADHD; it highlights sleep as an important, actionable part of care for people with monogenic epilepsies.
Collaborators from Weill Cornell, UC San Diego, and Karolinska University published their findings on the use of phenylbutyrate in 13 children with STXBP1 and 5 with SLC6A1-related disorders. Among STXBP1 children who previously had frequent, difficult‑to‑control seizures, most saw major reductions, some even became seizure‑free or were able to stop other seizure medications, though one STXer experienced an increase in seizures. Parents also described developmental gains such as better communication, more social interaction, improved attention, and new motor skills, though it was unclear how much of this progress was due to the phenylbutyrate versus natural development. Side effects from the medication were usually mild and short-lived but one preschool age child required hospitalization. Overall, the findings suggest phenylbutyrate may offer both seizure and mild developmental benefits for some children with STXBP1-RD.
A physician at University of Arkansas wrote a comprehensive review about what scientists and clinicians currently know about STXBP1-RD and the evolving therapeutic landscape. The article describes how symptoms typically begin in infancy, why development is so affected, and why seizures can follow different long‑term paths—some children improve while others continue to have difficult‑to‑control epilepsy. It also outlines current treatments, which mostly manage symptoms, and highlights the rapidly growing pipeline of precision therapies such as gene replacement, antisense oligonucleotides, gene manipulation, and targeted small molecule drugs. Overall, the review shows that STXBP1 is now a leading example of how understanding a single gene can drive targeted treatments aimed at improving both seizures and development.
Spanish researchers conducted a study using detailed 3-dimensional MRI measurements to compare brain structures in children with three synapse-related genetic conditions; STXBP1, SYNGAP1, and GRIN. They found both shared and gene‑specific differences the in brains compared to age-matched controls. Across all groups, certain deep brain regions were larger than expected while areas important for movement, coordination, and emotional processing, like the cerebellum, white matter, and limbic structures, were smaller. STXBP1 stood out for having the most pronounced cerebellar volume loss, along with thinning in parts of the corpus callosum (the part of the brain that connects the right and left hemispheres) and enlargement of the supplementary motor cortex, a pattern that may reflect how STXBP1 disrupts presynaptic signaling and especially affects inhibitory (GABA‑based) circuits. These structural differences align with the severe motor challenges, profound developmental delays, and epilepsy commonly seen in STXBP1-RD. Overall, the findings suggest that pathogenic variants in STXBP1 produces a distinct brain “signature,” and that advanced MRI could help clarify how this gene affects brain development and function.
